Can the use of bone marrow parameters improve the efficacy of risk prediction scores in chronic myeloid leukemia in imatinib era??
Abstract Introduction Many attempts have been made to develop risk prediction scores for chronic myeloid leukemia in chronic phase (CML-CP) to identify the subgroup with poorer response to therapy to intensify treatment modality early. As bone marrow (BM) provides a more sensitive reflection of the...
Gespeichert in:
| Veröffentlicht in: | Clinical lymphoma, myeloma and leukemia myeloma and leukemia, 2017-06, Vol.17 (6), p.375-381 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 381 |
|---|---|
| container_issue | 6 |
| container_start_page | 375 |
| container_title | Clinical lymphoma, myeloma and leukemia |
| container_volume | 17 |
| creator | Kanakasetty, Govind Babu Thanky, Aditi Harsh Kuntegowdanahalli, Lakshmaiah Dasappa, Lokanatha Jacob, Linu Mallekavu, Suresh Babu Lakkavalli, Rajeev Kadabur, Lokesh Antapura, Rudresha |
| description | Abstract Introduction Many attempts have been made to develop risk prediction scores for chronic myeloid leukemia in chronic phase (CML-CP) to identify the subgroup with poorer response to therapy to intensify treatment modality early. As bone marrow (BM) provides a more sensitive reflection of the disease process, we hypothesised that using BM parameters in sokal and EUTOS risk scores could improve their efficacy in imatinib treated population. Materials and Methods We analysed cases of CML-CP for their response and survival outcomes on imatinib based on risk groupings with Sokal and EUTOS scores using peripheral blood (PB) or BM parameters which were labelled as Sokal-PB, Sokal-BM, EUTOS-PB and EUTOS-BM. Results 371 cases were analysed. Concordance for risk groups was more for EUTOS scores (81.9%) than for Sokal scores (68.1%) for using PB versus BM parameters. For all the 4 risk scores, predictive efficacy was statistically significant. EUTOS-PB and EUTOS-BM could better prognosticate PFS and OS between its low and high risk groups (P |
| doi_str_mv | 10.1016/j.clml.2017.02.029 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1899112093</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S215226501630725X</els_id><sourcerecordid>1899112093</sourcerecordid><originalsourceid>FETCH-LOGICAL-c411t-754d384b28070d80efc4e2cb2133263aa1b7205e5c4ebdcf621c7888916034c63</originalsourceid><addsrcrecordid>eNp9kUuLFDEURoMozkP_gAvJ0k23eVSlqkAcpJlRYWAWo-AupG7dYtKdR5tUjfTWXz4pe5yFCyGQkJzvknsuIW84W3PG1fvtGpx3a8F4s2airO4ZORW8FiuhVPf86VyzE3KW85axhjHevSQnoq2ZqBQ7Jb83JtDpDumckcaR9jEg9Sal-IvuTTIeJ0yZWr9P8R7_kDiOFgwcFjzZvKP7hIOFycZAM8SEBQ8U7lIMFqg_oIt2oA7nHXprljfrzWSD7Skmc3HxirwYjcv4-nE_J9-vLr9tvqyubz5_3Xy6XkHF-bRq6mqQbdWLtrQxtAxHqFBAL7iUQkljeN8IVmNdrvsBRiU4NG3bdlwxWYGS5-TdsW5p5eeMedLeZkDnTMA4Z83bruNcsE4WVBxRSDHnhKPep_LpdNCc6cW93urFvV7caybK6kro7WP9ufc4PEX-yi7AhyOApct7i0lnsBig2EsIkx6i_X_9j__EwRWLYNwOD5i3cU6h-NNc5xLQt8v0l-FzJVkj6h_yAXCwqwI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1899112093</pqid></control><display><type>article</type><title>Can the use of bone marrow parameters improve the efficacy of risk prediction scores in chronic myeloid leukemia in imatinib era??</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Kanakasetty, Govind Babu ; Thanky, Aditi Harsh ; Kuntegowdanahalli, Lakshmaiah ; Dasappa, Lokanatha ; Jacob, Linu ; Mallekavu, Suresh Babu ; Lakkavalli, Rajeev ; Kadabur, Lokesh ; Antapura, Rudresha</creator><creatorcontrib>Kanakasetty, Govind Babu ; Thanky, Aditi Harsh ; Kuntegowdanahalli, Lakshmaiah ; Dasappa, Lokanatha ; Jacob, Linu ; Mallekavu, Suresh Babu ; Lakkavalli, Rajeev ; Kadabur, Lokesh ; Antapura, Rudresha</creatorcontrib><description>Abstract Introduction Many attempts have been made to develop risk prediction scores for chronic myeloid leukemia in chronic phase (CML-CP) to identify the subgroup with poorer response to therapy to intensify treatment modality early. As bone marrow (BM) provides a more sensitive reflection of the disease process, we hypothesised that using BM parameters in sokal and EUTOS risk scores could improve their efficacy in imatinib treated population. Materials and Methods We analysed cases of CML-CP for their response and survival outcomes on imatinib based on risk groupings with Sokal and EUTOS scores using peripheral blood (PB) or BM parameters which were labelled as Sokal-PB, Sokal-BM, EUTOS-PB and EUTOS-BM. Results 371 cases were analysed. Concordance for risk groups was more for EUTOS scores (81.9%) than for Sokal scores (68.1%) for using PB versus BM parameters. For all the 4 risk scores, predictive efficacy was statistically significant. EUTOS-PB and EUTOS-BM could better prognosticate PFS and OS between its low and high risk groups (P<0.0001). While for Sokal risk score use of BM parameters improved prognostic capacity for progression free survival (PFS) between low and intermediate groups with statistical significance (P=0.025) but not the overall survival (OS) (P=0.88). Conclusion Use of BM parameters, a simple mean that is feasible in routine clinical practice could improve prognostic efficacy of Sokal score with regards to PFS, but not the OS in low and intermediate risk groups. Further research to improve sensitivity of risk scores to prognosticate CML-CP and attempts at risk directed therapy is warranted.</description><identifier>ISSN: 2152-2650</identifier><identifier>EISSN: 2152-2669</identifier><identifier>DOI: 10.1016/j.clml.2017.02.029</identifier><identifier>PMID: 28502460</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adolescent ; Adult ; Aged ; Antineoplastic Agents - pharmacology ; Antineoplastic Agents - therapeutic use ; BM parameters ; Bone Marrow - metabolism ; CML ; EUTOS score ; Female ; Hematology, Oncology and Palliative Medicine ; Humans ; Imatinib Mesylate - pharmacology ; Imatinib Mesylate - therapeutic use ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology ; Male ; Middle Aged ; Peripheral blood parameters ; Retrospective Studies ; Risk Factors ; Sokal score ; Treatment Outcome ; Young Adult</subject><ispartof>Clinical lymphoma, myeloma and leukemia, 2017-06, Vol.17 (6), p.375-381</ispartof><rights>Elsevier Inc.</rights><rights>2017 Elsevier Inc.</rights><rights>Copyright © 2017 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c411t-754d384b28070d80efc4e2cb2133263aa1b7205e5c4ebdcf621c7888916034c63</citedby><cites>FETCH-LOGICAL-c411t-754d384b28070d80efc4e2cb2133263aa1b7205e5c4ebdcf621c7888916034c63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.clml.2017.02.029$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28502460$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kanakasetty, Govind Babu</creatorcontrib><creatorcontrib>Thanky, Aditi Harsh</creatorcontrib><creatorcontrib>Kuntegowdanahalli, Lakshmaiah</creatorcontrib><creatorcontrib>Dasappa, Lokanatha</creatorcontrib><creatorcontrib>Jacob, Linu</creatorcontrib><creatorcontrib>Mallekavu, Suresh Babu</creatorcontrib><creatorcontrib>Lakkavalli, Rajeev</creatorcontrib><creatorcontrib>Kadabur, Lokesh</creatorcontrib><creatorcontrib>Antapura, Rudresha</creatorcontrib><title>Can the use of bone marrow parameters improve the efficacy of risk prediction scores in chronic myeloid leukemia in imatinib era??</title><title>Clinical lymphoma, myeloma and leukemia</title><addtitle>Clin Lymphoma Myeloma Leuk</addtitle><description>Abstract Introduction Many attempts have been made to develop risk prediction scores for chronic myeloid leukemia in chronic phase (CML-CP) to identify the subgroup with poorer response to therapy to intensify treatment modality early. As bone marrow (BM) provides a more sensitive reflection of the disease process, we hypothesised that using BM parameters in sokal and EUTOS risk scores could improve their efficacy in imatinib treated population. Materials and Methods We analysed cases of CML-CP for their response and survival outcomes on imatinib based on risk groupings with Sokal and EUTOS scores using peripheral blood (PB) or BM parameters which were labelled as Sokal-PB, Sokal-BM, EUTOS-PB and EUTOS-BM. Results 371 cases were analysed. Concordance for risk groups was more for EUTOS scores (81.9%) than for Sokal scores (68.1%) for using PB versus BM parameters. For all the 4 risk scores, predictive efficacy was statistically significant. EUTOS-PB and EUTOS-BM could better prognosticate PFS and OS between its low and high risk groups (P<0.0001). While for Sokal risk score use of BM parameters improved prognostic capacity for progression free survival (PFS) between low and intermediate groups with statistical significance (P=0.025) but not the overall survival (OS) (P=0.88). Conclusion Use of BM parameters, a simple mean that is feasible in routine clinical practice could improve prognostic efficacy of Sokal score with regards to PFS, but not the OS in low and intermediate risk groups. Further research to improve sensitivity of risk scores to prognosticate CML-CP and attempts at risk directed therapy is warranted.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>BM parameters</subject><subject>Bone Marrow - metabolism</subject><subject>CML</subject><subject>EUTOS score</subject><subject>Female</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Imatinib Mesylate - pharmacology</subject><subject>Imatinib Mesylate - therapeutic use</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Peripheral blood parameters</subject><subject>Retrospective Studies</subject><subject>Risk Factors</subject><subject>Sokal score</subject><subject>Treatment Outcome</subject><subject>Young Adult</subject><issn>2152-2650</issn><issn>2152-2669</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kUuLFDEURoMozkP_gAvJ0k23eVSlqkAcpJlRYWAWo-AupG7dYtKdR5tUjfTWXz4pe5yFCyGQkJzvknsuIW84W3PG1fvtGpx3a8F4s2airO4ZORW8FiuhVPf86VyzE3KW85axhjHevSQnoq2ZqBQ7Jb83JtDpDumckcaR9jEg9Sal-IvuTTIeJ0yZWr9P8R7_kDiOFgwcFjzZvKP7hIOFycZAM8SEBQ8U7lIMFqg_oIt2oA7nHXprljfrzWSD7Skmc3HxirwYjcv4-nE_J9-vLr9tvqyubz5_3Xy6XkHF-bRq6mqQbdWLtrQxtAxHqFBAL7iUQkljeN8IVmNdrvsBRiU4NG3bdlwxWYGS5-TdsW5p5eeMedLeZkDnTMA4Z83bruNcsE4WVBxRSDHnhKPep_LpdNCc6cW93urFvV7caybK6kro7WP9ufc4PEX-yi7AhyOApct7i0lnsBig2EsIkx6i_X_9j__EwRWLYNwOD5i3cU6h-NNc5xLQt8v0l-FzJVkj6h_yAXCwqwI</recordid><startdate>20170601</startdate><enddate>20170601</enddate><creator>Kanakasetty, Govind Babu</creator><creator>Thanky, Aditi Harsh</creator><creator>Kuntegowdanahalli, Lakshmaiah</creator><creator>Dasappa, Lokanatha</creator><creator>Jacob, Linu</creator><creator>Mallekavu, Suresh Babu</creator><creator>Lakkavalli, Rajeev</creator><creator>Kadabur, Lokesh</creator><creator>Antapura, Rudresha</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20170601</creationdate><title>Can the use of bone marrow parameters improve the efficacy of risk prediction scores in chronic myeloid leukemia in imatinib era??</title><author>Kanakasetty, Govind Babu ; Thanky, Aditi Harsh ; Kuntegowdanahalli, Lakshmaiah ; Dasappa, Lokanatha ; Jacob, Linu ; Mallekavu, Suresh Babu ; Lakkavalli, Rajeev ; Kadabur, Lokesh ; Antapura, Rudresha</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c411t-754d384b28070d80efc4e2cb2133263aa1b7205e5c4ebdcf621c7888916034c63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>BM parameters</topic><topic>Bone Marrow - metabolism</topic><topic>CML</topic><topic>EUTOS score</topic><topic>Female</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Imatinib Mesylate - pharmacology</topic><topic>Imatinib Mesylate - therapeutic use</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Peripheral blood parameters</topic><topic>Retrospective Studies</topic><topic>Risk Factors</topic><topic>Sokal score</topic><topic>Treatment Outcome</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kanakasetty, Govind Babu</creatorcontrib><creatorcontrib>Thanky, Aditi Harsh</creatorcontrib><creatorcontrib>Kuntegowdanahalli, Lakshmaiah</creatorcontrib><creatorcontrib>Dasappa, Lokanatha</creatorcontrib><creatorcontrib>Jacob, Linu</creatorcontrib><creatorcontrib>Mallekavu, Suresh Babu</creatorcontrib><creatorcontrib>Lakkavalli, Rajeev</creatorcontrib><creatorcontrib>Kadabur, Lokesh</creatorcontrib><creatorcontrib>Antapura, Rudresha</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical lymphoma, myeloma and leukemia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kanakasetty, Govind Babu</au><au>Thanky, Aditi Harsh</au><au>Kuntegowdanahalli, Lakshmaiah</au><au>Dasappa, Lokanatha</au><au>Jacob, Linu</au><au>Mallekavu, Suresh Babu</au><au>Lakkavalli, Rajeev</au><au>Kadabur, Lokesh</au><au>Antapura, Rudresha</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Can the use of bone marrow parameters improve the efficacy of risk prediction scores in chronic myeloid leukemia in imatinib era??</atitle><jtitle>Clinical lymphoma, myeloma and leukemia</jtitle><addtitle>Clin Lymphoma Myeloma Leuk</addtitle><date>2017-06-01</date><risdate>2017</risdate><volume>17</volume><issue>6</issue><spage>375</spage><epage>381</epage><pages>375-381</pages><issn>2152-2650</issn><eissn>2152-2669</eissn><abstract>Abstract Introduction Many attempts have been made to develop risk prediction scores for chronic myeloid leukemia in chronic phase (CML-CP) to identify the subgroup with poorer response to therapy to intensify treatment modality early. As bone marrow (BM) provides a more sensitive reflection of the disease process, we hypothesised that using BM parameters in sokal and EUTOS risk scores could improve their efficacy in imatinib treated population. Materials and Methods We analysed cases of CML-CP for their response and survival outcomes on imatinib based on risk groupings with Sokal and EUTOS scores using peripheral blood (PB) or BM parameters which were labelled as Sokal-PB, Sokal-BM, EUTOS-PB and EUTOS-BM. Results 371 cases were analysed. Concordance for risk groups was more for EUTOS scores (81.9%) than for Sokal scores (68.1%) for using PB versus BM parameters. For all the 4 risk scores, predictive efficacy was statistically significant. EUTOS-PB and EUTOS-BM could better prognosticate PFS and OS between its low and high risk groups (P<0.0001). While for Sokal risk score use of BM parameters improved prognostic capacity for progression free survival (PFS) between low and intermediate groups with statistical significance (P=0.025) but not the overall survival (OS) (P=0.88). Conclusion Use of BM parameters, a simple mean that is feasible in routine clinical practice could improve prognostic efficacy of Sokal score with regards to PFS, but not the OS in low and intermediate risk groups. Further research to improve sensitivity of risk scores to prognosticate CML-CP and attempts at risk directed therapy is warranted.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>28502460</pmid><doi>10.1016/j.clml.2017.02.029</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2152-2650 |
| ispartof | Clinical lymphoma, myeloma and leukemia, 2017-06, Vol.17 (6), p.375-381 |
| issn | 2152-2650 2152-2669 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1899112093 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Adolescent Adult Aged Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use BM parameters Bone Marrow - metabolism CML EUTOS score Female Hematology, Oncology and Palliative Medicine Humans Imatinib Mesylate - pharmacology Imatinib Mesylate - therapeutic use Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology Male Middle Aged Peripheral blood parameters Retrospective Studies Risk Factors Sokal score Treatment Outcome Young Adult |
| title | Can the use of bone marrow parameters improve the efficacy of risk prediction scores in chronic myeloid leukemia in imatinib era?? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T10%3A03%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Can%20the%20use%20of%20bone%20marrow%20parameters%20improve%20the%20efficacy%20of%20risk%20prediction%20scores%20in%20chronic%20myeloid%20leukemia%20in%20imatinib%20era??&rft.jtitle=Clinical%20lymphoma,%20myeloma%20and%20leukemia&rft.au=Kanakasetty,%20Govind%20Babu&rft.date=2017-06-01&rft.volume=17&rft.issue=6&rft.spage=375&rft.epage=381&rft.pages=375-381&rft.issn=2152-2650&rft.eissn=2152-2669&rft_id=info:doi/10.1016/j.clml.2017.02.029&rft_dat=%3Cproquest_cross%3E1899112093%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1899112093&rft_id=info:pmid/28502460&rft_els_id=1_s2_0_S215226501630725X&rfr_iscdi=true |